spacer
home > ict > autumn 2009 > invisible technology
PUBLICATIONS
International Clinical Trials

Invisible Technology

 

I believe that, in many parts of life, technology is reaching the point where it is starting to become truly invisible. It is fading into the background of the main activities which it is there to facilitate, and it is at that point that the real value of the technology can be extracted. For instance, my car, through no particular effort of my own, routes me around traffic jams as I travel from place to place. My washing machine calculates how full it is and adjusts the cleaning time and programmes accordingly. My dishwasher knows how long to run wash programmes for (although I have no idea how). And my computer knows how I meant to spell things, and suggests searches I might use to find what it believes I am looking for. For EDC, I contend that it is the same fading of technology into the background that will bring about the next major advances in the day-to-day management of clinical trials. This revolution is already with us, offering the opportunity to extract significantly more value from EDC than I believe we presently demand. In this article, I attempt to explain why I believe that we have the potential to extract much more from EDC today, as well as a personal perspective of the development of the technology as I have experienced it over the last 20 years.

A PERSONAL HISTORY OF EDC

Twenty years ago, when I had just joined Pfizer, EDC was in its infancy. We had decided to run EDC on the Spanish part of a protocol which I was running in our Phase III programme. The system was completely customised – written from scratch on Apple Macs. Back then, our concept of the value proposition of an ideal EDC system was very broad. We were looking for a system which would: 

  • Reduce source data verification (which was just getting into the swing of 100 per cent checking) by encouraging investigators to put the data straight into the computer, thereby bypassing paper
  • Clean the data as you went, using inbuilt error checking, whilst eliminating scribbled notes on the margins of paper, which might indicate SAEs, and are easy to overlook

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Graham Wylie has 19 years’ experience in clinical trials, starting with 10 years at Pfizer in Clinical Development and Corporate HQ, with roles ranging from project management of trials to global implementation of standard trial processes and IT tools. He then joined Parexel International in 1999 as Medical Director for Northern Europe, progressing to Vice President of Account Management for Europe by 2003. In 2005, he joined Healthcare at Home to develop their clinical trials activities into a full business unit, known as ‘The Medical Research Network’, spinning the division off as a separate company, of which he is the CEO, in 2006.
spacer
Graham Wylie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement